Debate At PSA 2013: Can ‘Dream Team’ Approach To Scientific Innovation Work for Big Pharma?
This article was originally published in The Pink Sheet Daily
How best to tap scientific innovation? Identifying the top ‘true’ innovators and nurturing them and their ideas in-house may work for biotechs like Regeneron, but the fruits of such efforts are too rare to be reliable growth engines for big companies like Pfizer. That’s one takeaway from a lively R&D chiefs debate at Elsevier’s PSA 2013.